Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Agennix's overall survival in doubt as placebo beats talactoferrin in Ph III NSCLC

This article was originally published in Scrip

Executive Summary

The future of Agennix looks in doubt today after its oral recombinant lactoferrin product talactoferrin alfa failed to improve overall survival in a Phase III study in advanced non-small cell lung cancer (NSCLC) in patients who have received at least two prior therapies. The company's hopes had been riding on a positive outcome of this trial, FORTIS-M, after the drug failed a Phase II/III study in sepsis earlier in the year (scripintelligence.com, 3 February 2012).

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC018393

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel